31 Publications (Page 1 of 2)
2019
Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancerAwasthi, Niranjan⋅Kronenberger, David⋅Stefaniak, Alexis⋅Hassan, Md Sazzad⋅von Holzen, Urs⋅Schwarz, Margaret A and Schwarz, Roderich ECancer Letters, vol. 459, pp. 49, 2019-09-10.
| Journal Article
Therapeutic efficacy of anti‐MMP9 antibody in combination with nab‐paclitaxel‐based chemotherapy in pre‐clinical models of pancreatic cancerAwasthi, Niranjan⋅Mikels‐Vigdal, Amanda J⋅Stefanutti, Erin⋅Schwarz, Margaret A⋅Monahan, Sheena⋅Smith, Victoria and Schwarz, Roderich EJournal of Cellular and Molecular Medicine, vol. 23, (no. 6), pp. 3887, June 2019.
| Journal Article
2018
Abstract 4822: Anti-MMP9 antibody in combination with standard cytotoxic therapy in preclinical models of pancreatic cancerAwasthi, Niranjan⋅Mikels-Vigdal, Amanda⋅Stefanutti, Erin⋅Schwarz, Margaret A⋅Monahan, Sheena⋅Smith, Victoria and Schwarz, Roderich ECancer Research, vol. 78, (no. 13 Supplement), pp. 4822, 2018-07-01.
| Journal Article
Abstract 5807: The dual c-Met/VEGFR2 inhibitor foretinib augments chemotherapy response in preclinical models of gastric cancerAwasthi, Niranjan⋅Awasthi, Niranjan⋅Grojean, Meghan⋅Grojean, Meghan⋅Monahan, Sheena⋅Monahan, Sheena⋅Hassan, Sazzad⋅Hassan, Sazzad⋅Holzen, Urs von⋅Holzen, Urs von⋅Schwarz, Margaret A⋅Schwarz, Margaret A⋅Schwarz, Roderich E and Schwarz, Roderich ECancer Research, vol. 78, (no. 13 Supplement), pp. 5807, 2018-07-01.
| Journal Article
Augmentation of Nab -Paclitaxel Chemotherapy Response by Mechanistically Diverse Antiangiogenic Agents in Preclinical Gastric Cancer ModelsAwasthi, Niranjan⋅Schwarz, Margaret A⋅Zhang, Changhua and Schwarz, Roderich EMolecular cancer therapeutics, vol. 17, (no. 11), pp. 2364, 2018-11-00.
| Journal Article
Enhancing cytotoxic chemotherapy response through targeted BET bromodomain inhibition in preclinical pancreatic cancer modelsSingh, Sandeep⋅McCauley, Ross⋅Schwarz, Johann R⋅Schwarz, Roderich and Awasthi, NiranjanProceedings of IMPRS, vol. 1, (no. 1), 2018-12-07.
| Journal Article
Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancerAwasthi, Niranjan⋅Monahan, Sheena⋅Stefaniak, Alexis⋅Schwarz, Margaret A and Schwarz, Roderich EOncotarget, vol. 9, (no. 4), pp. 5286, 2018-Jan-12.
| Journal Article
2017
Abstract 4202: Trametinib, a MEK inhibitor, augments nab-paclitaxel based chemotherapy response in preclinical models of pancreatic cancerAwasthi, Niranjan⋅Monahan, Sheena⋅Stefaniak, Alexis⋅Schwarz, Margaret A and Schwarz, Roderich ECancer Research, vol. 77, (no. 13 Supplement), pp. 4202, 2017-07-01.
| Journal Article
2016
Adding targeted inhibition of PI3K and MAPK signaling pathways to standard chemotherapy in experimental pancreatic cancerAwasthi, Niranjan⋅Schwarz, Margaret A and Schwarz, RoderichJournal of Clinical Oncology, vol. 34, (no. 4_suppl), pp. 278, 2016-02-01.
| Journal Article
Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer modelsAwasthi, Niranjan⋅Scire, Emily⋅Monahan, Sheena⋅Grojean, Meghan⋅Zhang, Eric⋅Schwarz, Margaret A and Schwarz, Roderich EOncotarget, vol. 7, (no. 30), pp. 47001, 2016-Jul-26.
| Journal Article
2015
Abstract 3491: Enhancing nab-paclitaxel antitumor activity through addition of BMS-754807, a small-molecule inhibitor of IGF-1R/IR, in experimental pancreatic cancerAwasthi, Niranjan⋅Schwarz, Margaret A and Schwarz, Roderich ECancer Research, vol. 75, (no. 15 Supplement), pp. 3491, 2015-08-01.
| Journal Article
2014
Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic CancerAwasthi, Niranjan⋅Zhang, Changhua⋅Schwarz, Anna M⋅Hinz, Stefan⋅Schwarz, Margaret A and Schwarz, Roderich EMolecular cancer therapeutics, vol. 13, (no. 5), pp. 1043, 2014-May.
| Journal Article
Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancerAwasthi, Niranjan⋅Hinz, Stefan⋅Brekken, Rolf⋅Schwarz, Margaret and Schwarz, RoderichCancer Letters, vol. 358, (no. 1), pp. 66, 2014.
| Journal Article
2013
Abstract 2071: Addition of antiangiogenic agents enhances nab-paclitaxel antitumor activity in experimental pancreatic cancerAwasthi, Niranjan⋅Zhang, Changhua⋅Hinz, Stefan⋅Schwarz, Margaret A and Schwarz, Roderich ECancer Research, vol. 73, (no. 8 Supplement), pp. 2071, 2013-04-15.
| Journal Article
Comparative benefits of nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancerAwasthi, Niranjan⋅Ostapoff, Katherine T⋅Zhang, Changhua⋅Schwarz, Margaret A and Schwarz, RoderichJournal of Clinical Oncology, vol. 31, (no. 4_suppl), pp. 192, 2013-02-01.
| Journal Article
Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancerAwasthi, Niranjan⋅Awasthi, Niranjan⋅Zhang, Changhua⋅Zhang, Changhua⋅Schwarz, Anna M⋅Schwarz, Anna M⋅Hinz, Stefan⋅Hinz, Stefan⋅Wang, Changguang⋅Wang, Changguang⋅Williams, Noelle S⋅Williams, Noelle S⋅Schwarz, Margaret A⋅Schwarz, Margaret⋅Schwarz, Roderich and Schwarz, Roderich ECarcinogenesis, vol. 34, (no. 10), pp. 2369, 2013-Oct.
| Journal Article
Superior Antitumor Activity of Nanoparticle Albumin-Bound Paclitaxel in Experimental Gastric CancerZhang, Changhua⋅Zhang, Changhua⋅Awasthi, Niranjan⋅Awasthi, Niranjan⋅Schwarz, Margaret⋅Schwarz, Margaret A⋅Hinz, Stefan⋅Hinz, Stefan⋅Schwarz, Roderich and Schwarz, Roderich EPloS one, vol. 8, (no. 2), pp. e58037, 2013-00-00.
| Journal Article
The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancerZhang, Chang-Ηua⋅Zhang, Chang-Ηua⋅Awasthi, Niranjan⋅Awasthi, Niranjan⋅Schwarz, Margaret A⋅Schwarz, Margaret⋅Schwarz, Roderich E and Schwarz, RoderichInternational journal of oncology, vol. 43, (no. 5), pp. 1635, 2013-Nov.
| Journal Article
2012
Effect of NVP-BEZ235, a dual PI3K/mTOR inhibitor, on chemotherapy and antiangiogenic response in pancreatic cancerOstapoff, Katherine T⋅Awasthi, Niranjan⋅Yen, Peter L⋅Zhang, Changhua⋅Schwarz, Margaret A⋅Brekken, Rolf A and Schwarz, RoderichJournal of Clinical Oncology, vol. 30, (no. 4_suppl), pp. 243, 2012-02-01.
| Journal Article
Evaluation of combination treatment benefits of nab-paclitaxel in experimental pancreatic cancerAwasthi, Niranjan⋅Awasthi, Niranjan⋅Ostapoff, Katherine⋅Ostapoff, Katherine⋅Zhang, Changhua⋅Zhang, Changhua⋅Schwarz, Margaret A⋅Schwarz, Margaret A⋅Schwarz, Roderich and Schwarz, RoderichJournal of Clinical Oncology, vol. 30, (no. 4_suppl), pp. 170, 2012-02-01.
| Journal Article
Evaluation of Poly-Mechanistic Antiangiogenic Combinations to Enhance Cytotoxic Therapy Response in Pancreatic CancerAwasthi, Niranjan⋅Awasthi, Niranjan⋅Zhang, Changhua⋅Zhang, Changhua⋅Ruan, Winston⋅Ruan, Winston⋅Schwarz, Margaret⋅Schwarz, Margaret A⋅Schwarz, Roderich E and Schwarz, RoderichPloS one, vol. 7, (no. 6), pp. e38477, 2012-00-00.
| Journal Article
The efficacy of a novel, dual PI3K/mTOR inhibitor NVP‐BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancerAwasthi, Niranjan⋅Awasthi, Niranjan⋅Yen, Peter L⋅Yen, Peter L⋅Schwarz, Margaret A⋅Schwarz, Margaret⋅Schwarz, Roderich and Schwarz, Roderich EJournal of Cellular Biochemistry, vol. 113, (no. 3), pp. 791, March 2012.
| Journal Article
Use of PG545, a heparanase inhibitor, to inhibit pancreatic cancer tumor cell proliferation and migration in vitro and in vivoOstapoff, Katherine⋅Awasthi, Niranjan⋅Schwarz, Roderich and Brekken, Rolf AJournal of Clinical Oncology, vol. 30, (no. 4_suppl), pp. 234, 2012-02-01.
| Journal Article
2011
Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapyAwasthi, Niranjan⋅Awasthi, Niranjan⋅Awasthi, Niranjan⋅Schwarz, Margaret⋅Schwarz, Margaret⋅Schwarz, Margaret⋅Schwarz, Roderich⋅Schwarz, Roderich and Schwarz, RoderichCancer Chemotherapy and Pharmacology, vol. 68, (no. 3), pp. 582, 20110900.
| Journal Article
2010
Abstract 5387: Combination treatment benefits of EMAP II with doxorubicin, docetaxel and gemcitabine in experimental pancreatic cancerAwasthi, Niranjan⋅Schwarz, Margaret A and Schwarz, Roderich ECancer Research, vol. 70, (no. 8 Supplement), pp. 5387, 2010-04-15.
| Journal Article
